Immuron is no longer just a "concept" company. Global H1 FY26 sales grew to AUD$4.2 million, with the U.S. market showing strong momentum (+17% YoY).Cash ...

Consistent Revenue Growth: Immuron is no longer just a "concept" company. Global H1 FY26 sales grew to AUD$4.2 million, with the U.S. market showing strong momentum (+17% YoY). Cash (AUD $10.0 million ...

Exploring two complex cases of recurrent C. difficile infections unresponsive to antibiotics and FMT, and how naturopathic interventions supported long-term remission and restored quality of life. The ...

CLINICAL QUESTION: Is fecal microbiota transplantation (FMT) safe and efficacious in the treatment of primary Clostridioides difficile infection (CDI)? BACKGROUND: FMT is currently recommended for ...

(RTTNews) - Immuron (IMRN) announced the FDA has approved Investigational New Drug application for IMM-529 and the Phase 2 clinical trial may proceed. The company plans to initiate a Phase 2 clinical ...

Oral presentation highlights microbiome restoration through six months with REBYOTA from Phase 3b CDI-SCOPE trial New data from CDI-SCOPE evaluating the long-term safety of REBYOTA Retrospective ...

When it comes to treating C. diff infections (CDI), antibiotics are the standard of care. While antibiotics work for many, about 25% of patients face recurrent infections. When that happens, providers ...

Immuron submits Investigational new drug (IND) application to FDA for clinical development of IMM-529 as product to specifically prevent or treat Clostridioides difficile infection (CDI) Previous ...

Fecal microbiota transplantation (FMT), shown to be effective in the treatment of recurrent Clostridioides difficile infection (CDI), also shows significant benefit in the treatment of primary CDI, ...

1. In this randomized clinical trial, oral vancomycin reduced the risk of recurrent Clostridioides difficile infection (CDI) in participants with previous CDI, although not with a statistically ...